← Back to all trials
Active Not Recruiting
NCT04456322
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 381
Sponsor: Sun Yat-sen University
Location: Sun Yat-sen Universitty Cancer Center Guangzhou Guangdong
Summary
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction chemotheray(IC), determining whether radiotherapy combined with nimotuzumab was non-inferior to CCRT and may provide new evidence for individualized comprehensive treatment of locoregionally advanced NPC.
Eligibility Criteria
Inclusion Criteria:
1. Age 18-70, regardless of sex.
2. Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, type of WHO II or III, clinical stage II-IVa (except N3)(according to the 8th American Joint Committee on Cancer\[AJCC\] edition)
3. Patients with pre-treatment plasma EBV DNA\
Source: ClinicalTrials.gov (NCT04456322). StuddyBuddy aggregates publicly available trial information.
